Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future

Aviram Nissan, Alexander Stojadinovic, Alfredo Garofalo, Jesus Esquivel, Pompiliu Piso

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

The current treatment of peritoneal surface malignancies (PSMs) is moving from a nihilistic approach, into a combined modality approach offering selected patients long-term survival. As primary PSM are rare, extrapolation of data from clinical trials of related disease is necessary to develop treatment guidelines. Secondary PSM are more common, and therefore, treatment guidelines should be developed based on prospective clinical trials. We reviewed the published and ongoing clinical trials studying the treatment of PSM.

Original languageEnglish
Pages (from-to)335-344
Number of pages10
JournalJournal of Surgical Oncology
Volume100
Issue number4
DOIs
Publication statusPublished - Sep 15 2009

Fingerprint

Evidence-Based Medicine
Carcinoma
Clinical Trials
Neoplasms
Guidelines
Therapeutics
Survival

Keywords

  • Carcinomatosis
  • Clinical trial
  • Cytoreduction
  • Hyperthermic chemotherapy
  • Peritoneal surface malignancies

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Evidence-based medicine in the treatment of peritoneal carcinomatosis : Past, present, and future. / Nissan, Aviram; Stojadinovic, Alexander; Garofalo, Alfredo; Esquivel, Jesus; Piso, Pompiliu.

In: Journal of Surgical Oncology, Vol. 100, No. 4, 15.09.2009, p. 335-344.

Research output: Contribution to journalArticle

Nissan, Aviram ; Stojadinovic, Alexander ; Garofalo, Alfredo ; Esquivel, Jesus ; Piso, Pompiliu. / Evidence-based medicine in the treatment of peritoneal carcinomatosis : Past, present, and future. In: Journal of Surgical Oncology. 2009 ; Vol. 100, No. 4. pp. 335-344.
@article{642afed9f57d418c926ef33ab13c3b54,
title = "Evidence-based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future",
abstract = "The current treatment of peritoneal surface malignancies (PSMs) is moving from a nihilistic approach, into a combined modality approach offering selected patients long-term survival. As primary PSM are rare, extrapolation of data from clinical trials of related disease is necessary to develop treatment guidelines. Secondary PSM are more common, and therefore, treatment guidelines should be developed based on prospective clinical trials. We reviewed the published and ongoing clinical trials studying the treatment of PSM.",
keywords = "Carcinomatosis, Clinical trial, Cytoreduction, Hyperthermic chemotherapy, Peritoneal surface malignancies",
author = "Aviram Nissan and Alexander Stojadinovic and Alfredo Garofalo and Jesus Esquivel and Pompiliu Piso",
year = "2009",
month = "9",
day = "15",
doi = "10.1002/jso.21323",
language = "English",
volume = "100",
pages = "335--344",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Evidence-based medicine in the treatment of peritoneal carcinomatosis

T2 - Past, present, and future

AU - Nissan, Aviram

AU - Stojadinovic, Alexander

AU - Garofalo, Alfredo

AU - Esquivel, Jesus

AU - Piso, Pompiliu

PY - 2009/9/15

Y1 - 2009/9/15

N2 - The current treatment of peritoneal surface malignancies (PSMs) is moving from a nihilistic approach, into a combined modality approach offering selected patients long-term survival. As primary PSM are rare, extrapolation of data from clinical trials of related disease is necessary to develop treatment guidelines. Secondary PSM are more common, and therefore, treatment guidelines should be developed based on prospective clinical trials. We reviewed the published and ongoing clinical trials studying the treatment of PSM.

AB - The current treatment of peritoneal surface malignancies (PSMs) is moving from a nihilistic approach, into a combined modality approach offering selected patients long-term survival. As primary PSM are rare, extrapolation of data from clinical trials of related disease is necessary to develop treatment guidelines. Secondary PSM are more common, and therefore, treatment guidelines should be developed based on prospective clinical trials. We reviewed the published and ongoing clinical trials studying the treatment of PSM.

KW - Carcinomatosis

KW - Clinical trial

KW - Cytoreduction

KW - Hyperthermic chemotherapy

KW - Peritoneal surface malignancies

UR - http://www.scopus.com/inward/record.url?scp=69749097864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69749097864&partnerID=8YFLogxK

U2 - 10.1002/jso.21323

DO - 10.1002/jso.21323

M3 - Article

C2 - 19697442

AN - SCOPUS:69749097864

VL - 100

SP - 335

EP - 344

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -